DOCSLIB.ORG

Non-Confidential Report.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2009 Annual Report I. Table of Contents Pages Cover 1 Table of Contents 2 Overview of the Activities of the Taube-Koret Center for HD Research 3–5 Oversight of the Taube-Koret Center for HD Research Biographies of our Advisors 6 Report from Dr. Pagno Paganetti 7–10 Report from Dr. Norbert Bischofberger 11–13 Publications and Presentations of the Taube-Koret Center for HD Research Bibliography of Publications 14 HD-related Academic Seminars 15 HD-related Industry Consultations and Seminars 16 Taube-Koret Center for HD Research and the Community Press releases 17–22 News stories 23–33 The Taube-Koret Center for HD Research and 34 HD Families Appendix of Publications 35–113 2 II. Overview of the Activities of the Taube-Koret Center for Huntington’s Disease Research for 2009 We are pleased to provide this annual report describing the activities of the Taube-Koret Center for Huntington’s Disease Research during 2009. The Center was established in 2009 with a joint gift from Taube Philanthropies and the Koret Foundation. It has been a very exciting year. I am delighted to say that we exceeded all five of the scientific and financial goals we set for the first year of operation. Our progress in each area is described in detail below. Goal 1. Establish the Taube-Koret Center for Huntington’s Disease Our initial goal was to establish a Center focused on developing therapeutics for Huntington’s disease (HD). We proposed to develop an infrastructure that would be capable of identifying and validating drug targets for HD and of discovering compounds that modify HD and have the potential to become drugs. The new Center is housed in rented space within the Gladstone Center for Translational Research at 1700 Owens Street and in existing space within the main research building of the J. David Gladstone Institutes at 1650 Owens Street. The new laboratories have been outfitted with equipment to evaluate potential HD drug targets and to synthesize potential new therapeutics. Substantial capabilities, including special robotics, have been added to our existing laboratories to carry out high-throughput screens to find new therapeutics. One silver lining of the global financial crisis last year was that it enabled us to purchase equipment and set up these laboratories for less than it would otherwise have cost. Goal 2. Integrate industrial experience and capability into the academic framework In addition to the physical resources necessary to find HD therapeutics, we added critical human resources. Dr. Stephen Freedman provides assistance in prioritizing drug targets, designing screens, developing hits into lead programs, and negotiating relationships with potential industry partners. His decades of drug experience with Merck and Elan have proven to be extremely helpful. In addition, we recruited experts in medicinal chemistry to help us develop leads into potential drugs and established relationships with an array of contract research organizations that can perform critical steps in drug development that are not cost- effective to establish in house. We also recruited two external advisors of international reputation and drug discovery experience to provide a detailed scientific review of our program. Throughout the year, they have provided advice and oversight. In December, at our request, they made a site visit to review the program. The review meeting with Dr. Paolo Paganetti (Novartis) and Dr. Norbert Bischofberger (Gilead) was highly successful and added considerable input to our future direction. The detailed reports are provided below. Goal 3. Implement a critical review process and focus on programs most likely to succeed Recognizing that our resources are limited, we implemented a hard-nosed strategy to periodically re-prioritize our programs as results from our experiments become available. Programs that fail to meet performance criteria are dropped, and resources are redeployed to more promising leads. Programs that meet performance criteria and progress to the point that they interest industry are favored. They lead to partnerships that bring in additional resources from our industry partners, which also allow us to redeploy resources of the Center to other 3 promising leads. Industry partners will eventually be needed to carry leads forward into clinical trials, which require resources that are currently beyond those of the Center. We began the year with 11 programs, spanning target identification, validation, and lead development. By year’s end, one program was dropped because it failed to meet performance milestones. Another program had progressed to the point that it garnered interest by two competing biotechnology companies, who delivered term sheets to form a partnership. Three new lead programs have been added. Goal 4. Use a publication strategy to validate the scientific excellence of the Center, stimulate scientific discussion and promote scientific awareness in the Huntington’s disease field The scientific productivity of the Center during its first year has been exceptional. The Muchowski and Finkbeiner laboratories published 10 peer-reviewed papers describing results from their HD research programs. These studies revealed a range of pathogenic mechanisms in HD and therapeutic strategies. These include ground-breaking work on misfolding and abnormal clearance of huntingtin, critical neurobiology of cellular mechanisms to rid cells of protein aggregates, excessive neuroinflammation, new potential drugs to protect neurons against neurodegeneration induced by polyglutamine stretches, and new methods to use neurons to find therapeutics. A bibliography and copies of all the original publications from the Center in 2009 are enclosed. Publication is the major mechanism for achieving international renown for our HD research program. Other mechanism are to accept invitations to speak about the work from the Center all over the world and to participate in service to the National Institutes of Health (NIH) and on scientific advisory boards (SABs) of drug companies working on HD. Drs. Muchowski and Finkbeiner both helped to guide NIH HD programs in 2009 and provided SAB service and consultation to 11 biotechnology and pharmaceutical companies. As a result of these and other activities, the Center has been featured in the popular press. Some of these news stories can be found in this annual report. Goal 5. Leverage additional external funding to support the overall mission of the center Another important strategic feature of Center is our commitment to attract additional resources to leverage the investment by our donors. We were unusually successful in 2009, raising an additional $7.85M to support our HD therapeutics programs. A $1.7M grant from the prestigious Keck Foundation will enable us to establish a facility to study electrical activity in the region of the brain affected by HD in mice while they are awake and behaving. A $3.7M Grand Opportunity grant from the NIH will enable us to generate inducible pluripotent stem cells from skin tissue of adults with HD and use them to create human neurons we will use to search for new therapeutics. Further, the award itself provides additional recognition for the Center as one of the world’s leading sites for HD research. The remaining $2.45M came from the NIH in a series of smaller grants. We might never duplicate the fund raising success we experienced in 2009, but it was an encouraging start for the new Center nonetheless. 4 The Taube-Koret Center for Huntington’s Disease Research was established to facilitate the development of therapeutics for HD. We proposed a novel strategy to bridge the gap between academia and industry and to create a pipeline for therapeutics. This year, we expected to be heavily focused on building the infrastructure to develop therapeutics. However, we are pleased to report the unexpected news that two of our lead programs have already attracted industry interest. The fact that these programs have warranted industry interest is an important validation for the overall strategy of the Taube-Koret Center for Huntington’s Disease Research. The need for HD therapeutics is clear. Overall, we are very pleased with the success of the Taube-Koret Center for HD Research during its first year of operation. We remain as committed as ever to the primary goal of the Center—to develop therapies that prevent, treat, and eventually cure HD. Steven Finkbeiner, M.D., Ph.D. Paul Muchowski, Ph.D. Director, Taube-Koret Center Co-Director, Taube-Koret Center for Huntington’s Disease Research for Huntington’s Disease Research Associate Director, Senior Investigator Associate Investigator Gladstone Institute of Neurological Gladstone Institute of Neurological Disease Disease Professor, Departments of Neurology Associate Professor, Department and Physiology of Biochemistry and Biophysics UCSF UCSF 5 III. Reports of the External Advisors to the Taube-Koret Center for Huntington’s Disease Research We seek to be transparent and accountable in our management of the gifts entrusted to us by the donors, which enabled us to establish the Taube-Koret Center for Huntington’s Disease Research. As part of this effort, we recruited expert external advisors to the Center to provide an outside perspective on our performance. Short biographies of our advisors can be found below. The advisors provided advice and oversight throughout 2009. On December 15, 2009, we organized a day-long meeting on-site with our external advisors, who reviewed the structure of the Center and our major lead programs. Their reports are reproduced verbatim below. Biographies of the External Advisors to the Taube-Koret Center for Huntington’s Disease Research Paolo Paganetti, PhD Head of Huntington’s Disease Research Novartis Dr. Paganetti received his PhD from the University of Zurich, Switzerland in the lab of Prof. M.E. Schwab, in the Brain Research Institute. His postdoctoral research was done with Prof. Schwab and Prof. R.H. Scheller, HHMI and Stanford University. He joined Novartis in 1992 as a lab head and has occupied positions with increasing responsibilities.
Recommended publications
  • Collins Challenged Over NCI-Funded Research Linking Tea Party

    Collins Challenged Over NCI-Funded Research Linking Tea Party

    Vol. 39 No. 10 March 8, 2013 © Copyright 2013 The Cancer Letter Inc. All rights reserved. Price $405 Per Year. To subscribe, call 800-513-7042 or visit www.cancerletter.com. PO Box 9905 Washington DC 20016 Telephone 202-362-1809 Capitol Hill Collins Challenged Over NCI-Funded Research Capitol Hill Linking Tea Party With Tobacco Companies Collins: "I am quite By Paul Goldberg troubled by this NIH Director Francis Collins told a House subcommittee that he was “troubled” by a paper in which a prominent tobacco control expert, who particular circumstance." is funded by NCI, claims to have found a relationship between tobacco . Page 4 companies and the Tea Party conservative movement. The paper in question appeared in Tobacco Control, a peer-reviewed journal published by British Medical Journal Group. Drawing on documents Sequestration dating back to the 1980s and obtained from tobacco companies, the authors NCI Director Harold point to several instances in which the Tea Party and its predecessor Varmus Seeks to Protect organizations appear to act as proxies for tobacco interests. The paper cites Competitive Awards an NCI grant that supports analysis of tobacco industry documents. Page 5 The paper’s senior author is Stanton Glantz, professor in the Department of Medicine at the University of California San Francisco, a member of the Varmus' Address to Helen Diller Family Comprehensive Cancer Center, and director of the Center for Tobacco Control Research and Education. The NCI Board of (Continued to page 2) Scientific Advisors Sequestration . Page 7 Federal Budget Cuts Enacted March 1; HHS Agencies Grapple with Consequences BSA Approves RFA By Matthew Bin Han Ong Reissuance for the The across-the-board 5.1 percent budget cuts that went into effect March Pediatric Brain 1 slash the NIH budget by $1.553 billion and the NCI budget by $219 million for the remaining fiscal year, officials say.
  • Information-Seeking Behavior in Complementary and Alternative Medicine (CAM): an Online Survey of Faculty at a Health Sciences Campus*

    Information-Seeking Behavior in Complementary and Alternative Medicine (CAM): an Online Survey of Faculty at a Health Sciences Campus*

    Information-seeking behavior in complementary and alternative medicine (CAM): an online survey of faculty at a health sciences campus* By David J. Owen, M.L.S., Ph.D. [email protected] Education Coordinator, Basic Sciences Min-Lin E. Fang, M.L.I.S. [email protected] Information Services Librarian Kalmanovitz Library and Center for Knowledge Management University of California, San Francisco San Francisco, California 94143-0840 Background: The amount of reliable information available for complementary and alternative medicine (CAM) is limited, and few authoritative resources are available. Objective: The objective is to investigate the information-seeking behavior of health professionals seeking CAM information. Methods: Data were gathered using a Web-based questionnaire made available to health sciences faculty af®liated with the University of California, San Francisco. Results: The areas of greatest interest were herbal medicine (67%), relaxation exercises (53%), and acupuncture (52%). About half the respondents perceived their CAM searches as being only partially successful. Eighty-two percent rated MEDLINE as a useful resource, 46% personal contacts with colleagues, 46% the Web, 40% journals, and 20% textbooks. Books and databases most frequently cited as useful had information about herbs. The largest group of respondents was in internal medicine (26%), though 15% identi®ed their specialties as psychiatry, psychology, behavioral medicine, or addiction medicine. There was no correlation between specialty and patterns of information- seeking behavior. Sixty-six percent expressed an interest in learning more about CAM resources. Conclusions: Health professionals are frequently unable to locate the CAM information they need, and the majority have little knowledge of existing CAM resources, relying instead on MEDLINE.
  • University of California, Office of the President Records, 1914-1958

    University of California, Office of the President Records, 1914-1958

    http://oac.cdlib.org/findaid/ark:/13030/kt0489p7t8 No online items Guide to the University of California, Office of the President Records, 1914-1958 Processed by The Bancroft Library staff. The Bancroft Library. University of California, Berkeley Berkeley, California, 94720-6000 Phone: (510) 642-6481 Fax: (510) 642-7589 Email: [email protected] URL: http://bancroft.berkeley.edu © 2003 The Regents of the University of California. All rights reserved. Guide to the University of CU-5, Series 2 1 California, Office of the President Records, 1914-1958 Guide to the University of California, Office of the President Records, 1914-1958 Collection number: CU-5, Series 2 The Bancroft Library University of California, Berkeley Berkeley, California Contact Information: The Bancroft Library. University of California, Berkeley Berkeley, California, 94720-6000 Phone: (510) 642-6481 Fax: (510) 642-7589 Email: [email protected] URL: http://bancroft.berkeley.edu Processed by: The Bancroft Library staff Date Completed: September 2003 Encoded by: James Lake © 2003 The Regents of the University of California. All rights reserved. Collection Summary Collection Title: University of California, Office of the President records, Date (inclusive): 1914-1958 Collection Number: CU-5, Series 2 Creator: University of California (System). Office of the President Extent: 612.5 linear ft. Repository: The Bancroft Library. Berkeley, California 94720-6000 Physical Location: For current information on the location of these materials, please consult the Library's online catalog. Languages Represented: English Access The collection is open for research, although certain kinds of confidential information may be withheld if found. Publication Rights Copyright has not been assigned to The Bancroft Library.
  • Amy Elizabeth Herr

    Amy Elizabeth Herr

    Amy E. Herr, Ph.D. John D. & Catherine T. MacArthur Professor Bioengineering, University of California, Berkeley UNIVERSITY OF CALIFORNIA, Berkeley, CA 94720 BERKELEY [email protected] | herrlab.berkeley.edu EDUCATION 01/98 – 09/02 STANFORD UNIVERSITY Stanford, CA Doctor of Philosophy, Mechanical Engineering National Science Foundation Graduate Research Fellow “Isoelectric Focusing for Multi-Dimensional Separations in Microfluidic Devices” Advisors: Profs. Thomas W. Kenny & Juan G. Santiago 09/97 – 01/99 STANFORD UNIVERSITY Stanford, CA Master of Science, Mechanical Engineering National Science Foundation Graduate Research Fellow 09/93 – 06/97 CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH) Pasadena, CA Bachelor of Science, Engineering & Applied Science with Honors APPOINTMENTS 07/19 – now JOHN D. & CATHERINE T. MACARTHUR PROFESSOR, UNIVERSITY OF CALIFORNIA, BERKELEY 07/14 – 07/19 LESTER JOHN & LYNNE DEWAR LLOYD DISTINGUISHED PROFESSOR (5-year appointment), UC BERKELEY 07/12 – 07/15 ASSOCIATE PROFESSOR, BIOENGINEERING, UNIVERSITY OF CALIFORNIA, BERKELEY 07/07 – 07/12 ASSISTANT PROFESSOR, BIOENGINEERING, UNIVERSITY OF CALIFORNIA, BERKELEY UC BERKELEY/UCSF GRADUATE GROUP IN BIOENGINEERING Directing a research group focused on design and study of microanalytical tools and methods that exploit scale-dependent physics & chemistry to address questions in the biosciences and biomedicine. Chan Zuckerberg Biohub Investigator (2017-21), National Advisory Council for Biomedical Imaging and Bioengineering (2020-23), Faculty Director of Bakar Faculty Fellows Program (2016-now), Co-Convener of Chancellor’s Advisory Committee on Life Sciences (2019-22), BioE Vice-chair for Engagement (2016- now), Director’s Council for Jacobs Institute of Design Innovation, Board Member of Chemical & Biological Microsystems Society (2013-19; Awards Chair 2016-18), Director of Bioengineering Immersion Experience (2012-22; NIH R25).
  • Deptbiochemistry00ruttrich.Pdf

    Deptbiochemistry00ruttrich.Pdf

    'Berkeley University o'f California Regional Oral History Office UCSF Oral History Program The Bancroft Library Department of the History of Health Sciences University of California, Berkeley University of California, San Francisco The UCSF Oral History Program and The Program in the History of the Biological Sciences and Biotechnology William J. Rutter, Ph.D. THE DEPARTMENT OF BIOCHEMISTRY AND THE MOLECULAR APPROACH TO BIOMEDICINE AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO VOLUME I With an Introduction by Lloyd H. Smith, Jr., M.D. Interviews by Sally Smith Hughes, Ph.D. in 1992 Copyright O 1998 by the Regents of the University of California Since 1954 the Regional Oral History Office has been interviewing leading participants in or well-placed witnesses to major events in the development of Northern California, the West, and the Nation. Oral history is a method of collecting historical information through tape-recorded interviews between a narrator with firsthand knowledge of historically significant events and a well- informed interviewer, with the goal of preserving substantive additions to the historical record. The tape recording is transcribed, lightly edited for continuity and clarity, and reviewed by the interviewee. The corrected manuscript is indexed, bound with photographs and illustrative materials, and placed in The Bancroft Library at the University of California, Berkeley, and in other research collections for scholarly use. Because it is primary material, oral history is not intended to present the final, verified, or complete narrative of events. It is a spoken account, offered by the interviewee in response to questioning, and as such it is reflective, partisan, deeply involved, and irreplaceable.
  • Joint Meeting: Committees on Finance and Compensation

    Joint Meeting: Committees on Finance and Compensation

    The Regents of the University of California COMMITTEE ON FINANCE COMMITTEE ON COMPENSATION July 15, 2009 The Committees on Finance and Compensation met jointly on the above date at UCSF–Mission Bay Community Center, San Francisco. Members present: Representing the Committee on Finance: Regents Bernal, Garamendi, Island, Kozberg, Lozano, Makarechian, Schilling, Varner, and Wachter; Ex officio members Blum, Gould, and Yudof; Advisory member Croughan; Staff Advisors Abeyta and Martinez Representing the Committee on Compensation: Regents Johnson, Kozberg, Lozano, Stovitz, and Varner; Ex officio members Blum, Gould, and Yudof; Advisory members Croughan and Hime In attendance: Regents De La Peña, Kieffer, Lansing, Marcus, Nunn Gorman, Reiss, Ruiz, and Zettel, Regent-designate Cheng, Faculty Representative Powell, Secretary and Chief of Staff Griffiths, Associate Secretary Shaw, General Counsel Robinson, Chief Investment Officer Berggren, Chief Compliance and Audit Officer Vacca, Interim Provost Pitts, Executive Vice Presidents Lapp and Taylor, Senior Vice Presidents Dooley and Stobo, Vice Presidents Beckwith, Broome, Duckett, Lenz, and Sakaki, Chancellors Birgeneau, Bishop, Block, Blumenthal, Drake, Fox, Kang, Vanderhoef, White, and Yang, and Recording Secretary Johns The meeting convened at 10:20 a.m. with Committee on Finance Chair Lozano presiding. 1. AMENDMENT OF STANDING ORDER 100.4 – DUTIES OF THE PRESIDENT The President recommended that the Committees on Finance and Compensation recommend that: A. Pursuant to Bylaw 7.3, the requirements
  • Patrick J. H. Bradley

    Patrick J. H. Bradley

    (415) 734-2745 Patrick J. H. Bradley Gladstone Institutes, GIDB [email protected] 1650 Owens Street Pronouns: he/him/his Bioinformatics Fellow San Francisco, CA 94158 Current Position ······················································································· 2013— J. David Gladstone Institutes at UCSF Bioinformatics Fellow, Prof. Katherine S. Pollard Lab Academic History ····················································································· 2012—13 Lewis-Sigler Institute for Integrative Genomics, Princeton University Postdoctoral Fellow, Prof. Olga G. Troyanskaya Lab 2005—12 Dept. of Molecular Biology, Princeton University Ph.D. in Molecular Biology, Specialization in Quantitative and Computational Biology Thesis: Inferring Metabolic Regulation from High-Throughput Data Advisors: Prof. Joshua D. Rabinowitz, Prof. Olga G. Troyanskaya Committee: Prof. Ned S. Wingreen, Prof. David Botstein 2005 Dept. of Biology, Harvard College A.B. in Biology Peer-Reviewed Publications ·········································································· 1. Patrick H. Bradley, Katherine S. Pollard. “phylogenize: correcting for phylogeny reveals genes associated with microbial distributions.” Bioinformatics, 2019; btz722.∗;z 2. Patrick H. Bradley, Patrick A. Gibney, David Botstein, Olga G. Troyanskaya, Joshua D. Rabinowitz. “Minor isozymes tailor yeast metabolism to carbon availability.” mSystems, 2019; 4:e00170-18.∗;y 3. Patrick H. Bradley, Stephen Nayfach, Katherine S. Pollard. “Phylogeny-corrected identification
  • Research Grants

    Research Grants

    RESEARCH GRANTS 1 HDF RESEARCH GRANTS We like the philosophy of the Hereditary Disease Foundation that monies raised go directly to support research and that scientists from around the world “are encouraged to collaborate and share their work. “ We’ve devoted ourselves to being supporters and research partners, and we have not been disappointed. The research is vibrant with possibilities. Sandy Fox Member, Board of Directors Hereditary Disease Foundation 1 HDF RESEARCH GRANTS Osama Al-Dalahmah, MD, DPhil Anna Pluciennik, PhD Columbia University, New York, NY Thomas Jefferson University, Philadelphia, PA Cheryl Arrowsmith, PhD Paul Ranum, PhD University of Toronto, Canada Children’s Hospital of Philadelphia, PA Anne Ast, PhD Piere Rodriguez-Aliaga, PhD Max Delbrück Center for Molecular Medicine Stanford University, Palo Alto, CA Berlin, Germany Jennie C. L. Roy, PhD Kristina Becanovic, PhD Massachusetts General Hospital Karolinska Institutet, Stockholm, Sweden Harvard Medical School, Boston, MA Abdellatif Benraiss, PhD David M. Sabatini, MD, PhD University of Rochester, Rochester, NY Whitehead Institute for Biomedical Research Massachusetts Institute of Technology, Cambridge, MA Veronica Ines Brito, PhD University of Barcelona Charlene Smith-Geater, PhD Instituto de Neurosciencias, Spain University of California, Irvine, CA Lauren Byrne, PhD Joan Steffan, PhD University College London (UCL), England University of California, Irvine, CA Amit Laxmikant Deshmukh, PhD Xiao Sun, PhD The Hospital for Sick Children, Toronto, Canada Southwestern Medical Center, Dallas, TX Steven Finkbeiner, MD, PhD Leslie Thompson, PhD Gladstone Institutes University of California, Irvine, CA University of California, San Francisco, CA Nicholas Todd, PhD Brent Fitzwalter, PhD Brigham and Women’s Hospital Broad Institute of MIT and Harvard, Cambridge, MA Harvard Medical School, Boston, MA Ali Khoshnan, PhD Ray Truant, PhD California Institute of Technology, Pasadena, CA McMaster University, Ontario, Canada Ryan Lim, PhD Jean Paul G.
  • Preexposure Prophylaxis for HIV Infection Integrated with Municipal- and Community-Based Sexual Health Services

    Preexposure Prophylaxis for HIV Infection Integrated with Municipal- and Community-Based Sexual Health Services

    Research Original Investigation Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services Albert Y. Liu, MD, MPH; Stephanie E. Cohen, MD, MPH; Eric Vittinghoff, PhD; Peter L. Anderson, PharmD; Susanne Doblecki-Lewis, MD; Oliver Bacon, MD, MPH; Wairimu Chege, MD, MPH; Brian S. Postle, BS; Tim Matheson, PhD; K. Rivet Amico, PhD; Teri Liegler, PhD; M. Keith Rawlings, MD; Nikole Trainor, MPH; Robert Wilder Blue, MSW; Yannine Estrada, PhD; Megan E. Coleman, FNP; Gabriel Cardenas, MPH; Daniel J. Feaster, PhD; Robert Grant, MD, MPH; Susan S. Philip, MD, MPH; Richard Elion, MD; Susan Buchbinder, MD; Michael A. Kolber, PhD, MD Invited Commentary page 85 IMPORTANCE Several randomized clinical trials have demonstrated the efficacy of Supplemental content at preexposure prophylaxis (PrEP) in preventing human immunodeficiency virus (HIV) jamainternalmedicine.com acquisition. Little is known about adherence to the regimen, sexual practices, and overall effectiveness when PrEP is implemented in clinics that treat sexually transmitted infections (STIs) and community-based clinics serving men who have sex with men (MSM). OBJECTIVE To assess PrEP adherence, sexual behaviors, and the incidence of STIs and HIV infection in a cohort of MSM and transgender women initiating PrEP in the United States. DESIGN, SETTING, AND PARTICIPANTS Demonstration project conducted from October 1, 2012, through February 10, 2015 (last date of follow-up), among 557 MSM and transgender women in 2 STI clinics in San Francisco, California, and Miami, Florida, and a community health center in Washington, DC. Data were analyzed from December 18, 2014, through August 8, 2015. INTERVENTIONS A combination of daily, oral tenofovir disoproxil fumarate and emtricitabine was provided free of charge for 48 weeks.
  • Clinical Efficacy and Increased Donor Strain Engraftment After Antibiotic

    Clinical Efficacy and Increased Donor Strain Engraftment After Antibiotic

    medRxiv preprint doi: https://doi.org/10.1101/2021.08.07.21261556; this version posted August 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Clinical efficacy and increased donor strain engraftment after antibiotic pretreatment in a randomized trial of ulcerative colitis patients receiving fecal microbiota transplant Byron J. Smith A,B (ORCID: 0000-0002-0182-404X) Yvette Piceno C (ORCID: 0000-0002-7915-4699) Martin Zydek D Bing Zhang D (ORCID: 0000-0002-3377-0963) Lara Aboud Syriani E Jonathan P. Terdiman D Zain Kassam F Averil Ma G (ORCID: 0000-0003-4817-1258) Susan V. Lynch D,H (ORCID: 0000-0001-5695-7336) Katherine S. Pollard A,B,I,* (ORCID: 0000-0002-9870-6196) Najwa El-Nachef D,* A The Gladstone Institute of Datascience and Biotechnology, San Francisco, CA B Department of Epidemiology and Biostatistics, University of California, San Francisco, CA C Symbiome, Inc., San Francisco, CA D Division of Gastroenterology, University of California, San Francisco, CA E College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA F Finch Therapeutics, Somerville, MA G Department of Medicine, University of California, San Francisco, CA H Benioff Center for Microbiome Medicine, University of California, San Francisco, CA I Chan-Zuckerberg Biohub, San Francisco, CA * Corresponding authors: [email protected] [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
  • Millie Hughes-Fulford: Scientist in Space

    Millie Hughes-Fulford: Scientist in Space

    Millie Hughes-Fulford: Scientist in Space A resource for using QUEST video in the classroom Watch it online http://science.kqed.org/quest/video/millie-hughes-fulford-scientist-in-space/ | 9:59 minutes QUEST SUBJECTS PROGRAM NOTES NASA’s space program became a celebrated endeavor during the successful Moon Life Biology landing in 1969, but few people link NASA and medical research. At the inception of Science Health NASA’s Apollo Program in the 1960s, scientists discovered a link between gravity and Environment human health. As the government space program drew to an end in 2011, we visited former astronaut Millie Hughes-Fulford, the first woman to travel into space as a working Earth Geology scientist. She conducts experiments in space to further medical understanding. Science Climate Weather In this segment you’ll find… Astronomy .Physical Physics ۞ information on medical experiments done in space Science Chemistry Engineering ۞ a description of the immune system and the importance of T cells. an explanation of gravity’s influence on the human ۞ NEXT immune system. GENERATION SCIENCE STANDARDS TOPIC BACKGROUND High School At the time of first Apollo space missions, in the 1960s, half the astronauts became ill Disciplinary Core Ideas during their flight or soon after coming home. Scientists realized that the pull of Earth’s LS1.A: Structure and gravity helped keep the human body healthy. In a zero gravity environment, the human Function body experiences alterations at the cellular level that can lead to changes in muscle ESS1.B Earth and the Solar tissue, bone loss and problems in the immune system.
  • UCSF Medical Alumni Magazine

    UCSF Medical Alumni Magazine

    MAGAZINE MedicalAlumnfall i2008 volume 49 | no 2 Building a Campus at Parnassus Also inside... HIV/AIDS CARE IN BRAZIL | HOMECOMING 2008 | WELL-BEING PROGRAM Inside departments MedicalAlumni 1 from the editor 6 president’s letter 16 class notes MAGAZINE Fall 2008: Volume 49, Number 2 EdiTOR-IN-CHief: Kenneth H. Fye, MD ’68 MANAGING EdiTOR: Anne Kavanagh CONTRIBUTING EdiTORS: Gary Bernard, Debra Holcomb, Jean Murray WRITERS: Lisa Cisneros, Jody Duncan, Anne Kavanagh, Kate Volkman, Tina Vu PHOTOGRapHERS: Noah Berger, Earl McCowen, Fabricio Meneses, Susan Merrell, Mary Lane Vaz EdiTORiaL AssisTANTS: Gina Martinez, Michelle Pardo DesiGNER: Laura Myers Design Administrative Council 2008–2009 OFFICERS Lawrence Lustig, MD ’91, President; Lawrence Hill, MD ’67, President-Elect; TBD, Vice President (Northern California); H. John Blossom, MD ’70, Vice President (Central California); Ronald P. Karlsberg, MD ’73, Vice President (Southern California); Donna Hoghooghi, MD ’98, Secretary/Treasurer COUNCILORS AT LARGE features Robert J. Albo, MD ’59; Kenneth M. Bermudez, MD ’92; Caley Castelein, MD ’98; Neal H. Cohen, MD ’71; Timothy J. Crowley, MD ’80; Ruth Goldstein, MD ’79; 2 A Brazilian Love Story Uri Ladabaum, MD ’91; Tomas Magana, MD ’95; How Irene Adams, MD ’63, came to care for – and cherish – Brazil’s street kids. Mary Eleanor Margaretten, MD ’03; Gary Mizono, MD; Willis Navarro, MD ’90; Harlan B. Watkins, MD ’63; Jane Phillips, MD, President, Association of the 3 Black Caucus Honors Longtime UCSF Leader Clinical Faculty; Albert Hall, MD ’52, Councilor Emeritus; Statue pays homage to former dean of the School of Medicine, Haile Debas, MD, Robert C. Lim, MD ’60, Councilor Emeritus and his dedication to transforming health worldwide.